Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech

‘A silver lining’: how Covid ushered in a vaccines golden era

Pandemic accelerated advances in vaccine technology, opening up possibilities for combating array of diseases

The Guardian - UK

BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion

BioNTech said Monday it expects roughly $5.4 billion in sales of its Covid shot this year, missing views and leading BNTX stock to tumble.

Investors Business Daily

Rwanda welcomes Africa's first mobile vaccine-production units

Six mobile vaccine-production units developed by German pharmaceutical company BioNTech have arrived in Rwanda. This is the first such shipment to Africa as the continent seeks to boost local production of mRNA vaccines.

Radio France Internationale

From analysis to the latest developments in health,
read the most diverse news in one place.

What are these 'cancer vaccines' I'm hearing about? And what similarities do they share with COVID vaccines?

Barely a month goes by without headlines announcing yet another advancement in cancer vaccines.

The Conversation

What are these ‘cancer vaccines’ making news? Are there similarities with COVID vaccines?

Using the same mRNA technology as COVID vaccines, cancer vaccines are an emerging personalised treatment for cancer.

The New Daily

The Next Generation Of Cancer Vaccines Is Coming; What That Means For Moderna And Other Biotech Stocks

Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know.

Investors Business Daily

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees

Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

The Independent UK

In synthetic biology, startups and incumbent companies should be partners, not foes

In this crucial area of innovation, established companies and startups must work together to deliver the benefits that the science promises.

Fortune

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip

Novavax plans to update its Covid vaccine for new variants, and NVAX stock outperformed its vaccine stock rivals.

Investors Business Daily

‘This will happen before 2030’: how the science behind Covid vaccines might help to fight cancer

The success of mRNA-based drugs in combating coronavirus is inspiring scientists to create similar vaccines for melanoma and other tumours

The Guardian - UK

At buzzy health care business conference, investors fear the bubble will burst

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

WEKU

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

Salon

Mainlanders seek mRNA vaccines in Hong Kong

HONG KONG: Scores of mainland Chinese travellers are rushing to Hong Kong to receive mRNA Covid-19 vaccines, which are not available on the Chinese mainland, as the country grapples with a torrent of infections that have overwhelmed its health system.

Bangkok Post

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Mainland Chinese head to Hong Kong for mRNA COVID vaccines

Scores of mainland Chinese travellers are rushing to Hong Kong to receive mRNA COVID-19 vaccines, which are not available on the Chinese mainland, as the country grapples with a torrent of infections which have overwhelmed its health system.

The Conversation

Cancer vaccine trials could start in the autumn – UK signs deal with BioNTech

The UK government recently announced that it is partnering with German firm BioNTech to test vaccines for cancer and other diseases. The project aims to build on the mRNA vaccine technology that BioNTech became famous for developing, and which has been so successful at preventing serious illness and death from…

ABC News

Plan for mRNA cancer vaccine trials to start in United Kingdom this year

Personalised cancer vaccine trials in England will roll out this year after the United Kingdom government signed a deal with a company behind one of the major COVID-19 vaccines.

Caixin Global

Chinese Mainlanders Can Book Omicron-Specific mRNA Shot in Hong Kong

Fosun Pharma opens online reservation platform for BioNTech vaccination as Covid border controls are set to end

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks

If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks.

Evening Standard

UK signs groundbreaking mRNA cancer vaccine research agreement

The partnership with German pharmaceutical company BioNTech will be one of the first of its kind

The Independent UK

UK speeds up plans to develop mRNA vaccines for cancer patients with BioNTech deal

Deal follows UK’s largely successful Covid vaccine roll out

The Guardian - UK

Cancer vaccine trials could start in England by autumn

Government deal with BioNTech paves way for early access to trials of personalised mRNA therapies

Reuters

BioNTech signs deal with UK for personalised cancer therapies

BioNTech SE has signed a deal with the UK government to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said.

Wales Online

UK Health Secretary to sign cancer treatments deal for patients in England

Steve Barclay is set to sign a memorandum of understanding with BioNTech to ensure high quality cancer treatments are available as soon as possible

The Independent UK

Health Secretary to sign cancer treatments deal with leading pharmaceutical company

Steve Barclay is due to sign a memorandum of understanding with BioNTech on Friday.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.